Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 4/2018

01-12-2018 | Lung Cancer (R Mudad, Section Editor)

Pneumonitis in Patients with Lung Cancer Following Treatment: the Effects of Chemotherapy, Immunotherapy, and Tyrosine Kinase Inhibitors

Authors: Matthew P. Salzberg, Brian Hunis, Luis Raez

Published in: Current Pulmonology Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

Multiple articles have been written on the development of pneumonitis as it relates to each class of treatment options in NSCLC. To date, there are no articles that review pulmonary side effects seen in all agents including chemotherapy, immunotherapy, and TKIs that are used in NSCLC. Our goal was to identify these agents, review the pathophysiology, and establish treatment options when pneumonitis develops. In doing so, we have established a resource for physicians treating this disease.

Recent Findings

Within the past decade, significant strides have been made in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Targeted agents, namely tyrosine kinase inhibitors (TKIs) and immunotherapy have established themselves and shifted the treatment paradigm in this disease, they also brought along very specific and different toxicities, such as pneumonitis. Cytotoxic chemotherapy continues to play a major role as single agent, combined therapy, or in combination with immunotherapy. Within each of these classes of treatment options, pulmonary side effects are possible.

Summary

Multiple articles have been written on the development of pneumonitis as it relates to each class of treatment options in NSCLC. To date, there are no articles that review pulmonary side effects seen in all agents including chemotherapy, immunotherapy, and TKIs that are used in NSCLC. Our goal was to identify the agents, review the pathophysiology, and establish treatment options when pneumonitis develops. In doing so, we have established a resource for physicians treating this disease.
Literature
1.
Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71(4):301–26.CrossRef
2.
Bonniaud P, Georges M, Favrolt N, Camus P. [Drug-induced interstitial lung diseases]. Rev Prat. 2014;64(7):951–6.PubMed
3.
Fujimoto D, Kato R, Morimoto T, Shimizu R, Sato Y, Kogo M, et al. Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung Cancer. PLoS One. 2016;11(12):e0168465.CrossRef
4.
Dhokarh R, Li G, Schmickl CN, Kashyap R, Assudani J, Limper AH, et al. Drug-associated acute lung injury: a population-based cohort study. Chest. 2012;142(4):845–50.CrossRef
5.
Limper AH. Chemotherapy-induced lung disease. Clin Chest Med. 2004;25(1):53–64.CrossRef
6.
Leger P, Limper AH, Maldonado F. Pulmonary toxicities from conventional chemotherapy. Clin Chest Med. 2017;38(2):209–22.CrossRef
7.
Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 2008;133(2):528–38.CrossRef
8.
Dimopoulou I, Galani H, Dafni U, Samakovii A, Roussos C, Dimopoulos MA. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer. 2002;94(2):452–8.CrossRef
9.
Yerushalmi R, Kramer MR, Rizel S, Sulkes A, Gelmon K, Granot T, et al. Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study. Ann Oncol. 2009;20(3):437–40.CrossRef
10.
Wardley AM, Hiller L, Howard HC, Dunn JA, Bowman A, Coleman RE, et al. tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. Br J Cancer. 2008;99(4):597–603.CrossRef
11.
Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Muller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol. 2002;57(4):292–9.CrossRef
12.
Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology. 2011;258(1):41–56.CrossRef
13.
Aapro MS, Martin C, Hatty S. Gemcitabine--a safety review. Anti-Cancer Drugs. 1998;9(3):191–201.CrossRef
14.
Roychowdhury DF, Cassidy CA, Peterson P, Arning M. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Investig New Drugs. 2002;20(3):311–5.CrossRef
15.
Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80(2):286–91.CrossRef
16.
Linskens RK, Golding RP, van Groeningen CJ, Giaccone G. Severe acute lung injury induced by gemcitabine. Neth J Med. 2000;56(6):232–5.CrossRef
17.
Marruchella A, Fiorenzano G, Merizzi A, Rossi G, Chiodera PL. Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J. 1998;11(2):504–6.CrossRef
18.
Barlesi F, Villani P, Doddoli C, Gimenez C, Kleisbauer JP. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol. 2004;18(1):85–91.CrossRef
19.
Boiselle PM, Morrin MM, Huberman MS. Gemcitabine pulmonary toxicity: CT features. J Comput Assist Tomogr. 2000;24(6):977–80.CrossRef
20.
Sauer-Heilborn A, Kath R, Schneider CP, Hoffken K. Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol. 1999;125(11):637–40.CrossRef
21.
Umemura S, Yamane H, Suwaki T, Katoh T, Yano T, Shiote Y, et al. Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer. J Cancer Res Clin Oncol. 2011;137(10):1469–75.CrossRef
22.
Blackstock AW, Lesser GJ, Fletcher-Steede J, Case LD, Tucker RW, Russo SM, et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;51(5):1281–9.CrossRef
23.
van Putten JW, Price A, van der Leest AH, Gregor A, Little FA, Groen HJ. A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res. 2003;9(7):2472–7.PubMed
24.
Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Investig New Drugs. 1996;14(3):257–63.CrossRef
25.
Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Miller AA, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002;20(20):4191–8.CrossRef
26.
Jeter MD, Janne PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002;53(2):394–400.CrossRef
27.
Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S, Mehrotra B. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol. 2002;25(1):96–100.CrossRef
28.
Vander Els NJ, Miller V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest. 1998;114(6):1779–81.CrossRef
29.
Gurjal A, An T, Valdivieso M, Kalemkerian GP. Etoposide-induced pulmonary toxicity. Lung Cancer. 1999;26(2):109–12.CrossRef
30.
Hatakeyama S, Tachibana A, Morita M, Suzuki K, Okano H. [Etoposide-induced pneumonitis]. Nihon Kyobu Shikkan Gakkai Zasshi. 1997;35(2):210–4.PubMed
31.
Uchida T, Nakakawaji K, Sakamoto J. Administration of oral etoposide for one year as adjuvant chemotherapy for non-small cell lung cancer-side effect. Gan To Kagaku Ryoho. 1996;23(14):1967–70.PubMed
32.
Ostoros G, Pretz A, Fillinger J, Soltesz I, Dome B. Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature. Int J Gynecol Cancer. 2006;16(Suppl 1):391–3.CrossRef
33.
Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, et al. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res. 2012;32(3):1103–6.PubMed
34.
Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol. 2006;17(3):372–9.CrossRef
35.
Graziano SL, Herndon JE 2nd, Socinski MA, Wang X, Watson D, Vokes E, et al. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol. 2008;3(2):158–62.CrossRef
36.
Bielopolski D, Evron E, Moreh-Rahav O, Landes M, Stemmer SM, Salamon F. Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. J Chemother. 2017;29(2):113–7.CrossRef
37.
Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer. 2001;85(9):1247–50.CrossRef
38.
Stemmer SM, Cagnoni PJ, Shpall EJ, Bearman SI, Matthes S, Dufton C, et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol. 1996;14(5):1463–72.CrossRef
39.
McNeish IA, Kanfer EJ, Haynes R, Giles C, Harland SJ, Driver D, et al. Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours. Br J Cancer. 2004;90(6):1169–75.CrossRef
40.
Thomas AL, Cox G, Sharma RA, Steward WP, Shields F, Jeyapalan K, et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer. 2000;36(18):2329–34.CrossRef
41.
Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329–34.CrossRef
42.
Katakami N, Takiguchi Y, Yoshimori K, Isobe H, Bessho A, Yoshimura A, et al. Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol. 2006;1(5):447–53.CrossRef
43.
Takeda K, Negoro S, Tamura T, Nishiwaki Y, Kudoh S, Yokota S, et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol. 2009;20(5):835–41.CrossRef
44.
Briasoulis E, Froudarakis M, Milionis HJ, Peponis I, Constantopoulos S, Pavlidis N. Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support. Respiration. 2000;67(6):680–3.CrossRef
45.
Kalmadi S, McNeill G, Davis M, Peereboom D, Adelstein D, Mekhail T. Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Med Oncol. 2006;23(4):507–13.CrossRef
46.
Nakamura M, Koizumi T, Hayasaka M, Yasuo M, Tsushima K, Kubo K, et al. Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer. Cancer Chemother Pharmacol. 2009;63(6):1091–6.CrossRef
47.
Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, Araki T, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer. 2003;40(1):79–84.CrossRef
48.
Hasegawa T, Futamura Y, Horiba A, Yoshida T, Suzuki T, Kato T, et al. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer. J Radiat Res. 2016;57(1):50–4.CrossRef
49.
Amathieu R, Tual L, Fessenmeyer C, Dhonneur G. Docetaxel-induced acute pulmonary capillary-leak syndrome mimicking cardiogenic oedema. Ann Fr Anesth Reanim. 2007;26(2):180–1.CrossRef
50.
Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced Cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607–16.CrossRef
51.
Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051–60.CrossRef
52.
Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709–17.CrossRef
53.
Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50(2).
54.
• Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152(2):271–81. This paper provides good insight in regards to pulmonary toxicites of checkpoint inhibitors. CrossRef
55.
Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94(1):107–16.CrossRef
56.
• Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015:76–83. Good overview of immune related side effects. CrossRef
57.
Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092–9.CrossRef
58.
•• Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–68. An excellent review in the management if immunotherapy related toxicities. CrossRef
59.
Lemons J, Luke JJ, Karrison T, et al. Safety and clinical activity of pembrolizumab and multi-organ site ablative stereotactic body radiotherapy in patients with advanced solid tumors. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. Abstract 20. Presented January 25, 2018.
60.
Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-year follow-up of Nivolumab in previously treated advanced non-small-cell lung Cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675–84.CrossRef
61.
William WN Jr, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009;136(3):701–9.CrossRef
62.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.CrossRef
63.
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823–33.CrossRef
64.
Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–508.CrossRef
65.
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104.CrossRef
Metadata
Title
Pneumonitis in Patients with Lung Cancer Following Treatment: the Effects of Chemotherapy, Immunotherapy, and Tyrosine Kinase Inhibitors
Authors
Matthew P. Salzberg
Brian Hunis
Luis Raez
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Pulmonology Reports / Issue 4/2018
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-018-0219-y

Other articles of this Issue 4/2018

Current Pulmonology Reports 4/2018 Go to the issue

Interstitial Lung Disease (A. Hajari Case, Section Editor)

Connective Tissue Related Interstitial Lung Disease

Interstitial Lung Disease (A. Hajari Case, Section Editor)

Nonpharmacological Therapies for Interstitial Lung Disease

Interstitial Lung Disease (A. Hajari Case, Section Editor)

Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis

Lung Transplant (R Bag, Section Editor)

Lung Transplantation in Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)

COPD and Asthma (W Calhoun, Section Editor)

The Use and Interpretation of Impedance Oscillometry in Pulmonary Disorders

COPD and Asthma (W Calhoun, Section Editor)

Evidence-Based Assessment of Bronchial Thermoplasty in Asthma: Mechanisms and Outcomes

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits